Search clinical trials for: IPSS-R intermediate

Total 998 results

Forma Therapeutics, Inc.

Recruiting

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

United States, France, Canada, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Ning Xu
The First Affiliated Hospital of Nanchang University; Zhongshan Hospital Xiamen... and other collaborators

Not yet recruiting

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

Prostate Cancer | Surgical Procedure, Unspecified
Priovant Therapeutics, Inc.

Not yet recruiting

A Phase 3 Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) (CLARITY)

Uveitis | Uveitis, Posterior | Uveitis, Intermediate
Cairo University

Recruiting

Analgesic Efficacy of an Intermediate CPB in Neck Surgeries.

Anesthesia | Thyroid | Neck | Bupivacaine

Egypt
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma (TRESOR)

Adult With Intermediate Low or Mid Rectal Adenocarcinoma

France
NYU Langone Health

Recruiting

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Ryvu Therapeutics SA

Not yet recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
The First Affiliated Hospital of Soochow University

Recruiting

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High Risk Acute Myeloid Leukemia | Intermediate Risk Acute Myeloid Leukemia

China
Cerenovus, Part of DePuy Synthes Products, Inc.

Not yet recruiting

Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke (SPLENDID)

Acute Ischemic Stroke

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

Assesment of Intermediate Vision After BIL Cataract Surgery

Cataract
Supergene, LLC

Not yet recruiting

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Pulmonary Embolism

Russian Federation
Universidade Nova de Lisboa
iNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM,... and other collaborators

Recruiting

Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study (Imaging4iAMD)

Age-Related Macular Degeneration

Portugal
Medical University of Vienna
University of Zurich; Centre Hospitalier Universitaire Dijon; Fundacion Clinic... and other collaborators

Not yet recruiting

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression (SUDETES)

Age-Related Macular Degeneration
Rennes University Hospital

Not yet recruiting

Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer. (ROBOT-ECO-GYN)

Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma

France
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Unidade Local De Saúde Do Norte Alentejano
NOVA Medical School

Recruiting

Opportunistic Gastric Cancer Screening (ROCGAS)

Gastric Cancer

Portugal
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
Hospices Civils de Lyon

Not yet recruiting

Food Biodiversity and Human Health (BIOQUALIM)

Periodontal Diseases | Oral Microbiota

France
IRCCS Sacro Cuore Don Calabria di Negrar

Not yet recruiting

Low and Intermediate Risk oliGometastatic coloREctal cancEr patieNts Treated With Stereotactic ABlative Radiotherapy (GREENLaIT-SABR)

Colorectal Cancer

Italy
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
Fundación EPIC

Recruiting

Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions (EMPERATRIZ)

Coronary Disease

Spain
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma

United States
Medical University of Warsaw

Recruiting

Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome (MultiInter-CCS)

Chronic Coronary Syndrome

Poland
University of Virginia

Recruiting

Magnesium and Riboflavin Treatment for Post-Concussion Headache

Concussion, Intermediate

United States
Göteborg University
University of Manitoba; University of Pennsylvania

Recruiting

Effects of Railway Vibration on Sleep and Disease (BioVib)

Cognitive Change | Sleep Disturbance | Metabolic Disturbance | Noise Exposure | Vibration; Exposure | Sleep Hygiene | Glucose Metabolism Disorders (Including Diabetes Mellitus)

Sweden
Qianfoshan Hospital

Recruiting

A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

Carcinoma, Hepatocellular

China
British Columbia Cancer Agency
University of British Columbia; Vancouver Prostate Centre; BC Cancer Foundation

Recruiting

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer (BrachyTRACKS)

Localized Prostate Carcinoma

Canada
Saint Vincent's Hospital, Korea

Recruiting

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention (ALMIGHTY)

Coronary Artery Disease | Dyslipidemias | Primary Prevention

Korea, Republic of
Sunnybrook Health Sciences Centre

Recruiting

De-escalated Dose SBRT in Localized Prostate Cancer (DESTINATION-MRL)

Prostate Cancer

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; First Affiliated Hospital... and other collaborators

Recruiting

TEER for Severe DMR of Low to Intermediate Surgery Risk

Mitral Regurgitation

China
Niguarda Hospital

Recruiting

Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism (USAT IH-PE)

Pulmonary Embolism

Italy
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Non-Invasive Biomarkers in Prostate Cancer Disease Management

Prostate Cancer

United States
NHS Lothian

Not yet recruiting

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance (PRECISION)

Low Risk Prostate Cancer | Intermediate Risk Prostate Cancer | Localized Prostate Cancer
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
Centre Hospitalier Universitaire de Nīmes

Recruiting

Impact of Training on the Use of Software and Digital Monitoring Tools During General Anesthesia for Intermediate/Major-risk Surgery on Morbidity and Mortality at 28 Days (AoA QUALITY)

All Conditions Requiring Non-cardiac Surgery

France
Yale University
Pfizer

Recruiting

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
Massachusetts Eye Research and Surgery Institution
Eli Lilly and Company

Recruiting

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Uveitis, Anterior | Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States
Algemeen Ziekenhuis Maria Middelares

Recruiting

Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction (GDFT DIEP-flap)

Hypotension During Surgery

Belgium
Sejong General Hospital
Seoul St. Mary's Hospital; Pusan National University Hospital; Ulsan University... and other collaborators

Recruiting

Resting Full-cycle Ratio (RFR)-Guided Revascularization

Coronary Artery Disease

Korea, Republic of
Lantheus Medical Imaging

Recruiting

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer (MIRROR)

Prostate Cancer

United States
Asian Institute of Gastroenterology, India

Not yet recruiting

Application of Machine Learning Models to Reduce Need for Diagnostic EUS or MRCP in Patients With Intermediate Likelihood of Choledocholithiasis

Choledocholithiasis

Search clinical trials for: IPSS-R intermediate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations